- This event has passed.
Oct 24th: Olivier Adotevi
24 October @ 15 h 30 min - 16 h 30 min UTC+1
Regional Institute of Cancer, University Hospital of BESANCON
Immunomolecular Therapies in Cancer, INSERM UMR1098
Title: ” Prospects of telomerase-specific CD4 T cell responses in anti-cancer immunotherapy ”
Abstract: CD4 + Th1 cells play a critical role in tumor immunosurveillance by orchestrating cell-
mediated immunity against cancer cells. Furthermore, evidence indicates that triggering
appropriate CD4 + T cells can significantly increase cancer immunotherapy efficacy. These
properties highlight the interest of finding ways to harness the clinical potential of CD4 + T
cells. By using telomerase (TERT) as a prototype of shared tumor-associated antigen, our
team develops a research program that aims to study the regulation and clinical significance
of tumor-reactive CD4 Th1 response in peripheral blood. We also initiated an innovative
anticancer vaccine project using TERT-derived helper peptides designated to stimulate CD4
Th1 responses in vivo.